Beta2-mimetic and Central Nervous System

Not Applicable

Completed

• Conditions: Albuterol Effect; Adrenergic Beta-2 Agonist Effect
• Interventions: Drug: Placebo; Drug: Salbutamol

• Registration Number: NCT02925130
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.

Detailed Description

The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2016-10-03
• Study First Submitted QC: 2016-10-03
• Study First Posted: 2016-10-05
• Status Verified: 2017-03
• Primary Completion: 2017-09-28
• Study Completion: 2017-09-28
• Last Update Submitted: 2017-09-29
• Last Update Posted: 2017-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

• Healthy subjects without respiratory and cordiovascular diseases
• Male
• Age between 18 and 35
• Trained subjects (>6 hours of physical activity per week)
• Non- or ex-smoker (smoking cessation since at least 1 year)

Exclusion Criteria

• Respiratory, cardiovascular and metabolic diseases
• Neuromuscular diseases
• thyrotoxicosis, or diabetes treated with insulin
• alcoholism
• MRI contraindication
• TMS contraindication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Acute oral intake of a placebo
Inhaled Salbutamol	Salbutamol	Acute inhalation of 800 microgram Salbutamol
Oral Salbutamol	Salbutamol	Acute oral intake of 4 mg Salbutamol

Primary Outcome Measures

Name	Time	Method
Maximal voluntary activation	Measured immediatly after treatment intake (within 1 h)	Measurement performed by using transcranial magnetic stimulation, superimposed on submaximal and maximal quadricep contractions

Secondary Outcome Measures

Name	Time	Method
Exercise endurance	Measured immediatly after treatment intake (within 1 h)	Time to exhaustion during the exercise muscle test.
Cortical activation	Measured immediatly after treatment intake (within 1 h)	Measurement performed by using magnetic resonance imaging and the intensity of the BOLD signal in response to a motor task.

Trial Locations

Locations (1)

Grenoble University Hospital; 🇫🇷 Grenoble, France